Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin
- PMID: 10547586
- DOI: 10.1002/(SICI)1096-9896(199910)189:2<273::AID-PATH413>3.0.CO;2-4
Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin
Abstract
Although a multisystem disease, systemic sclerosis (SSc) most commonly affects the skin. The skin lesion is characterized by progressive changes, chief amongst which are vascular abnormalities, including endothelial cell (EC) injury and death, and dermal fibrosis. The pathogenesis of the vascular changes, and their relationship to dermal fibrosis, is poorly understood. The purpose of this study was to examine the potential role of nitric oxide (NO)-related free radical production, as part of an assessment of mechanisms leading to endothelial damage. Histologically graded skin biopsies from 33 patients with SSc (ten grade 0, ten grade 1, eight grade 2, and five grade 3) and eight healthy controls were reacted with antibodies against constitutive (eNOS) and inducible (iNOS) forms of nitric oxide synthase and nitrotyrosine. The degree of staining was assessed using a semi-quantitative system and a staining score was developed for the ECs of different vessel types in different areas of dermis at all grades. In biopsies from patients with SSc, superficial microvessel ECs showed a peak of eNOS expression in grade 1 skin which fell as the grade increased. By contrast, iNOS staining increased with the grade of skin lesion, a pattern paralleled by endothelial nitrotyrosine expression. From these findings, it is concluded that a metabolic switch occurs in dermal ECs from endothelial to cytokine inducible forms of NOS during the progression of the skin lesion of SSc. iNOS is a potent inducer of NO production which, in turn, can mediate NO free radical production. At a time of development of the SSc skin lesion when previous studies report evidence of EC damage, the cells express immunodetectable nitrotyrosine, a marker of NO-mediated free radical injury. The data suggest a role for iNOS-induced NO production in EC damage in SSc.
Copyright 1999 John Wiley & Sons, Ltd.
Similar articles
-
Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis.J Rheumatol. 1998 Feb;25(2):314-7. J Rheumatol. 1998. PMID: 9489825
-
Constitutive endothelial and inducible nitric oxide synthase in inflammatory dermatoses.Br J Dermatol. 1997 Jan;136(1):18-23. Br J Dermatol. 1997. PMID: 9039289
-
Upregulation of endothelial nitric oxide synthase maintains nitric oxide production in the cerebellum of thioacetamide cirrhotic rats.Neuroscience. 2004;126(4):879-87. doi: 10.1016/j.neuroscience.2004.04.010. Neuroscience. 2004. PMID: 15207323
-
NO bioavailability, endothelial dysfunction, and acute renal failure: new insights into pathophysiology.Semin Nephrol. 2004 Jul;24(4):316-23. doi: 10.1016/j.semnephrol.2004.04.003. Semin Nephrol. 2004. PMID: 15252771 Review.
-
Modulation of Nitric Oxide Synthases by Oxidized LDLs: Role in Vascular Inflammation and Atherosclerosis Development.Int J Mol Sci. 2019 Jul 4;20(13):3294. doi: 10.3390/ijms20133294. Int J Mol Sci. 2019. PMID: 31277498 Free PMC article. Review.
Cited by
-
Oncostatin M and its role in fibrosis.Connect Tissue Res. 2019 Jan;60(1):40-49. doi: 10.1080/03008207.2018.1500558. Epub 2018 Jul 30. Connect Tissue Res. 2019. PMID: 30056769 Free PMC article. Review.
-
Effects of micronutrient antioxidants (alpha-tocopherol and ascorbic acid) on skin thickening and lung function in patients with early diffuse systemic sclerosis.Rheumatol Int. 2011 Aug;31(8):1051-4. doi: 10.1007/s00296-010-1398-1. Epub 2010 Mar 23. Rheumatol Int. 2011. PMID: 20309694 Clinical Trial.
-
The clinical effects of l-arginine and asymmetric dimethylarginine: implications for treatment in secondary Raynaud's phenomenon.J Eur Acad Dermatol Venereol. 2019 Mar;33(3):497-503. doi: 10.1111/jdv.15180. Epub 2018 Aug 28. J Eur Acad Dermatol Venereol. 2019. PMID: 30004597 Free PMC article. Review.
-
Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis.Ann Rheum Dis. 2007 Sep;66(9):1202-9. doi: 10.1136/ard.2006.067504. Epub 2007 Mar 15. Ann Rheum Dis. 2007. PMID: 17363403 Free PMC article.
-
Vasculopathy in scleroderma.Semin Immunopathol. 2015 Sep;37(5):489-500. doi: 10.1007/s00281-015-0505-5. Epub 2015 Jul 8. Semin Immunopathol. 2015. PMID: 26152638 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical